阿拉普利
化合物
阿拉普利(INN:alacepril)是一种ACE抑制剂药物,可用于治疗高血压。该药物代谢为卡托普利和去乙酰阿拉普利。[1]阿拉普利主要用于治疗高血压,在某些情况下用于治疗肾血管性高血压。它通常与其他药物结合使用,特别是其他降血压药物,如噻嗪类利尿剂,以最大限度地发挥其功效。[2]
临床资料 | |
---|---|
AHFS/Drugs.com | 国际药品名称 |
给药途径 | 口服 |
ATC码 |
|
法律规范状态 | |
法律规范 |
|
识别信息 | |
| |
CAS号 | 74258-86-9 |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化学信息 | |
化学式 | C20H26N2O5S |
摩尔质量 | 406.50 g·mol−1 |
3D模型(JSmol) | |
| |
|
作用机制
在体内,当阿拉普利经历脱乙酰化时,它会失去类似于苯丙氨酸的分子,从而将其转化为卡托普利。[3]卡托普利通过两种方式发挥降血压作用。首先,它抑制血管紧张素1(一种前体分子)转化为血管紧张素II(一种使血管变窄的血管收缩剂)的过程。其次,卡托普利可以防止缓激肽的分解,缓激肽是一种自然松弛血管的血管舒张肽。[4]
参考资料
- ^ Alacepril. IBM Micromedex. 24 August 2010 [23 June 2022].
- ^ Alacepril. DrugCentral online drug compendium. [13 April 2024].
It is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. It used for the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics).
- ^ Campese VM, Lakdawala RS. The Challenges of Blood Pressure Control in Dialysis Patients. Nissenson AR, Fine RN (编). Handbook of dialysis therapy 5th. Philadelphia, PA: Elsevier. 2017. ISBN 978-0-323-39154-2. doi:10.1016/B978-0-323-39154-2.00053-9.
The sulfhydryl agents, such as alacepril, delapril, and moveltopril, are prodrugs and thus are converted to captopril in vivo. These sulfhydryl-containing compounds have a slower onset and longer duration of action than captopril.
- ^ Odaka C, Mizuochi T. Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals. Clinical and Experimental Immunology. September 2000, 121 (3): 515–522. PMC 1905724 . PMID 10971519. doi:10.1046/j.1365-2249.2000.01323.x.